Value
6.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 7.3 |
| P/S | 9.1 |
| EV/EBITDA | 6.8 |
| Fwd P/E | 5.4 |
- ▸Forward P/E: 23.6x
PBYI · Why this verdict
Why Puma Biotechnology (PBYI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock has formed a golden cross and trades above all major moving averages with bullish MACD, a technical breakout setup. Chart pattern detection | Price should remain above key moving averages and the breakout structure should hold over the next 12 months. | →Stable |
| CounterGolden-cross breakouts in speculative biotech names can fail quickly, especially when the asymmetry ratio is already deeply negative and analyst upside is exhausted. | ||
The company has beaten consensus EPS estimates in all of its last 4 quarters, with an average surprise near 86%. Catalyst breakdown | The company should continue beating consensus in at least 3 of the next 4 quarters. | →Stable |
| CounterBeats this large and consistent in a royalty-dependent biotech can reflect a low or volatile earnings base rather than durable operating strength. | ||
The stock has already reached its prior analyst price target, with the model flagging -48.5% modeled upside from the current level. Warnings | A new, higher price target should be established to justify further appreciation over the next 12 months. | →Stable |
| CounterReaching or exceeding a prior target with a deeply negative asymmetry ratio typically signals the stock is overextended rather than poised for a re-rating higher. | ||
Insiders have engaged in notable selling, totaling roughly $572,745 (0.14% of market cap), creating tension against the bullish technical breakout. Insider breakdown | Insider transactions should turn neutral or bullish over the next 12 months. | →Stable |
| CounterInsider selling into a breakout, especially with the target already reached, often signals that those closest to the business see the rally as an opportunity to reduce exposure rather than a start of a larger move. | ||
An elevated put/call ratio of 5.00, high implied volatility (72%), and a price above max pain ($8) all point to substantial options-market hedging or speculative bearish activity. Risk breakdown | The put/call ratio should normalize toward 2.0 or below over the next 12 months. | →Stable |
| CounterElevated puts in a volatile, high-IV biotech name could also reflect routine hedging by long holders rather than a directional bearish signal. | ||
The stock has formed a golden cross and trades above all major moving averages with bullish MACD, a technical breakout setup.
→StableChart pattern detection
- Expectation
- Price should remain above key moving averages and the breakout structure should hold over the next 12 months.
CounterGolden-cross breakouts in speculative biotech names can fail quickly, especially when the asymmetry ratio is already deeply negative and analyst upside is exhausted.
The company has beaten consensus EPS estimates in all of its last 4 quarters, with an average surprise near 86%.
→StableCatalyst breakdown
- Expectation
- The company should continue beating consensus in at least 3 of the next 4 quarters.
CounterBeats this large and consistent in a royalty-dependent biotech can reflect a low or volatile earnings base rather than durable operating strength.
The stock has already reached its prior analyst price target, with the model flagging -48.5% modeled upside from the current level.
→StableWarnings
- Expectation
- A new, higher price target should be established to justify further appreciation over the next 12 months.
CounterReaching or exceeding a prior target with a deeply negative asymmetry ratio typically signals the stock is overextended rather than poised for a re-rating higher.
Insiders have engaged in notable selling, totaling roughly $572,745 (0.14% of market cap), creating tension against the bullish technical breakout.
→StableInsider breakdown
- Expectation
- Insider transactions should turn neutral or bullish over the next 12 months.
CounterInsider selling into a breakout, especially with the target already reached, often signals that those closest to the business see the rally as an opportunity to reduce exposure rather than a start of a larger move.
An elevated put/call ratio of 5.00, high implied volatility (72%), and a price above max pain ($8) all point to substantial options-market hedging or speculative bearish activity.
→StableRisk breakdown
- Expectation
- The put/call ratio should normalize toward 2.0 or below over the next 12 months.
CounterElevated puts in a volatile, high-IV biotech name could also reflect routine hedging by long holders rather than a directional bearish signal.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Puma Biotechnology shows a technical breakout and a perfect earnings beat streak, but the stock has already reached its prior price target, faces notable insider selling, and shows heavy bearish options positioning that together argue against adding to the position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 7.2 |
| ROA | 6.3 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 5.4 |
| Current ratio | 8.1 |
| FCF quality | 10.0 |
| Moat | 7.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 181% FCF/NI
- ▸Rule of 40: 17 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
1.9/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 1.9 |
- ▸Declining revenue: -3%
Momentum
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 8.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 1.2 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 0.9 |
| erm sentiment | 5.0 |
- ▸Below analyst target
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $572,745 (0.136% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.8 |
| quality rank | 7.7 |
| growth rank | 3.2 |
- ▸Superior ROE vs peers
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.2 |
| support resistance | 0.9 |
| 52w position | 9.6 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.7 |
| days to cover | 0.0 |
| volatility | 1.8 |
| put call | 0.0 |
| implied vol | 0.2 |
| max pain risk | 3.0 |
| beta | 6.2 |
| debt equity | 9.5 |
- ▸Elevated put/call: 5.00
- ▸High IV: 79%
- ▸Above max pain $5
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:4.8>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-3.2=NEGATIVE
Warning (1)
- MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-3.24
Upside
-48.5%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 69, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.6 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Catalyst at 7.5) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-3.2=NEGATIVE) reinforce the read. Current asymmetry R:R is -3.24 — supplementary context, not the trigger for this path.
The strongest dimensions are Catalyst at 7.5, Quality at 6.6, and Value at 6.3; the weakest are Growth at 1.9, Risk (lower is worse) at 3.3, and Insider at 3.3. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -3.24 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Golden Cross Breakout Setup
Trip ifPrice falls below the 50-day moving average.
- P2Perfect Earnings Beat Streak
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Analyst Target Already Reached
Trip ifA new analyst price target is not issued above the current price within 2 quarters and the asymmetry ratio stays below -2.0.
- P4Notable Insider Selling Against Breakout
Trip ifInsider selling exceeds $1.5 million over a rolling 90-day window.
- P5Elevated Put Call Bearish Hedging
Trip ifPut/call ratio rises above 8.0.